Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 956 Neoplasms 755 Carcinoma, Non-Small-Cell Lung 742 Prostatic Neoplasms 569 Colorectal Neoplasms 499 Lung Neoplasms 444 Neoplasm Metastasis 400 Multiple Myeloma 371 Leukemia, Myeloid, Acute 351 Ovarian Neoplasms 307 Pancreatic Neoplasms 301 Melanoma 273 Squamous Cell Carcinoma of Head and Neck 257 Recurrence 248 Carcinoma, Hepatocellular 229 Glioblastoma 223 Brain Neoplasms 219 Head and Neck Neoplasms 199 Triple Negative Breast Neoplasms 198 Carcinoma, Renal Cell 197 Precursor Cell Lymphoblastic Leukemia-Lymphoma 190 Lymphoma 188 Stomach Neoplasms 186 Endometrial Neoplasms 177 Lymphoma, Non-Hodgkin 172 Sarcoma 168 Glioma 165 Uterine Cervical Neoplasms 160 Lymphoma, Large B-Cell, Diffuse 160 Hematologic Neoplasms 157

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced HER2+Breast Cancer × 90 days × Clear all

NCT04208178 2026-04-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡